Magdalena holds an MSc in Pharmaceutical Bioscience and an interdisciplinary PhD merging the fields of psychiatry, immunology and neuropharmacology. Her previous research focused on metabolic and immunologic changes in psychotic disorders. She is now focusing on science writing, allowing her to culture her passion for medical science and human health.
A research team at Southern Methodist University (SMU) in Dallas, Texas, has identified three compounds that were able to reverse resistance to chemotherapy in ovarian tumors. In lab experiments based ... Read more
The U.S. Food and Drug Administration (FDA) has granted Priority Review Status to Clovis Oncology’s application to expand its approval for Rubraca (rucaparib) to include recurrent ovarian cancer maintenance treatment. ... Read more
Cytori Therapeutics reports that their compound ATI-0918 is equivalent to Janssen’s Caelyx (doxorubicin) — a previously approved liposomal formulation of doxorubicin hydrochloride for the treatment of ovarian cancer. The data ... Read more
Siamab Therapeutics’ preclinical work with anti-STn antibody-drug conjugates is moving forward, and in animal models — including primates — it showed the conjugates could safely and effectively treat ovarian ... Read more
Clovis Oncology seeks to expand its approval for Rubraca (rucaparib) to include maintenance therapy for women with recurrent ovarian cancer who respond to platinum-based chemotherapy. The company, based in ... Read more
Half of ovarian cancer patients in a small study responded to a combination of Tesaro’s Zejula and Genentech’s Avastin, according to a presentation Tesaro made at the European Society of Medical Oncology (ESMO) ... Read more
Rubraca (rucaparib) maintenance treatment significantly improved survival without further disease progression among ovarian cancer patients taking part in a Phase 3 clinical trial, researchers showed in a presentation at the ongoing European ... Read more